PTC/SB/08a/b (07-05)
Approved for use through 07/31/2006. OMB 0551-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

_	stitute for form 1449A/	R/PTO		Complete If Known			
0020	NFORMATION DISCLOSUR STATEMENT BY APPLICAN		Application Number	09/589,288			
IN	FORMATI	ON DISC	CLOSURE	Filing Date	June 8, 2000		
S	TATEMEN'	T BY AF	PLICANT	First Named Inventor	Guo-Liang Yu		
				Art Unit	1647		
	(Use as man	y sheets as ne	cessary)	Examiner Name	B.E. Bunner		
Sheet	1	of	5	Attorney Docket Number	PF343P3C7		

			U.S. PA	TENT DOCUMENTS	
Examiner Initials*	Cite	Document Number	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant
inioais	No.'	Number-Kind Code ² (If known)			Figures Appear
BEB	J1	US2002/0037852 A1	03-28-2002	Browning et al.	
i	J2	US2002/0150579 A1	10-17-2002	Kimberly et al.	
	J3	US2003/0059937 A1	03-27-2003	Ruben et al.	
	J4	US2003/0095967 A1	05-22-2003	MacKay et al.	
	J5	US2003/0148445 A1	08-07-2003	Shu	
	J6	US2003/0166546 A1	09-04-2003	Aggarwal	
	J7	US2005/0100548 A1	05-12-2005	Browning et al.	
	J8	US2005/0244411 A1	11-03-2005	MacKay et al.	
	J9	6,403,770	06-11-2002	Yu et al.	
	J10	6,562,579	05-13-2003	Yu et al.	
	J11	6,635,482	10-21-2003	Yu et al.	
	J12	6,689,579	02-10-2004	Yu et al.	
	J13	6,716,576	04-06-2004	Yu et al.	
	J14	09/302,863	ÑA	Immunex Corp.	
	J15	60/149,378	NA	Mackay, F., et al.	
	J16	09/255,794	NA	Yu, G., et al.	
		60/119,906	NA	Boyle, W. and Hsu, H.	
	J18	60/166,271	NA	Boyle, W. and Hsu, H.	
	J19	09/226,533	NA	Gross, J., et al.	
	J20	60/157,933	NA	Schneider, P., et al.	
BEB	J21	5,595,721	01-21-1997	Kaminski et al.	

		FOREI	GN PATENT	DOCUMENTS		
Examiner	Cite	Foreign Patent Document	Publication Date	Name of Patentee or	Pages, Columns, Lines, Where Relevant Passages	ą.
Initials*	No.1	Country Code*-Number*-Kind Code* (if known)	MM-DD-YYYY	Applicant of Cited Document	or Relevant Figures Appear	۳
BEB	J22	WO99/35170 A2	07-15-1999	Genentech, Inc.		
1	J23	WO01/87977 A3	11-22-2001	Amgen, Inc.		
	J24	WO01/60397 A1	08-23-2001	Genentech, Inc.		
	J25	WO04/074511 A1	09-02-2004	Garvan Institute of Medical]	
	1		L	Research		
	J26	WO05/005462 A3	01-10-2005	Genentech, Inc.		
	J27	WO05/042009 A1		Biogen IDEC MA, Inc.		
	J28	EP 1 354 598 A3	10-22-2003	ZymoGenetics, Inc.		
	J29	EP 1 415 659 A1	05-06-2004	Biogen, Inc. and Apoxis SA		
	J30	EP 1 146 892 B1	08-20-2003	Biogen, Inc., Apoxis SA		
	J31	EP 1 141 274 B1	09-10-2003	ZymoGenetics, Inc.		
	J32	WO98/39361 A1	09-11-1998	St. Jude Children's Research Hospital		
	J33	WO01/12812 A2	02-22-2001	Biogen, Inc. and Apotech R & D SA		
	J34	WO01/24811 A1	04-12-2001	Biogen, Inc. and Apotech R & D SA		
BEB	J35	WO02/066516 A3	08-29-2002	ZymoGenetics, Inc.		

Examiner /Bridget E. Bunner/	Date Considered	07/19/2006

rror! Unknown document property name.

PTO/SB/08a/b (07-05)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

S. I	stitute for form 1449A/B	/PTO			Complete if Known
500	SUIGIO 101 101111 1443/40			Application Number	09/589,288
11	IFORMATIC	ON DIS	SCLOSURE	Filing Date	June 8, 2000
S	STATEMENT BY APPLICANT			First Named Inventor	Guo-Liang Yu
				Art Unit	1647
	(Use as many sheets as necessary)			Examiner Name	B.E. Bunner
Sheet	2	of	5	Attorney Docket Number	PF343P3C7

		FORE	GN PATENT	DOCUMENTS		
Examiner Initials*	Cite No.1	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁸ (# known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pagas, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T°
BEB	J36	EP 9828628.9	NA	Glaxo Group Ltd.		

		NON PATENT LITERATURE DOCUMENTS	
Examiner Cité Initials No.		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Τ°
BEB	J37	Human Genome Sciences' opposition of EP Patent No 1 146 892 B1 including Annex A. Filed in the European Patent Office on September 19, 2005.	
BEB	J38	Serono International SA's opposition of EP Patent No 1 146 892 B1 with Annexes I and II. Filed in the European Patent Office on August 24, 2005	
	J39	Lexikon der Medizin "Hypertension"	L
BEB	J40	WALLACH, D. "TNF Ligands and TNF/NGF Receptor Families" in Cytokine Reference Vol.1: Ligands, eds., Oppenheim and Feldman, Academic Press, pp. 377-411. (2001).	
	J41	Corixa Corporation's opposition of EP Patent No 1 141 274 B1. Filed in the European Patent Office on June 6, 2004.	
	J42	Human Genome Science's opposition of EP Patent No 1 141 274 B1. Filed in the European Patent Office on June 7, 2004.	
	J43	Genentech's opposition of EP Patent No 1 141 274 B1. Filed in the European Patent Office on June 10, 2004.	
	J44	Biogen IDEC's opposition of EP Patent No 1 141 274 B1. Filed in the European Patent Office on June 10, 2004.	
	J45	NARDELLI ET AL., "B Lymphocyte Stimulator (BLyS): a therapeutic trichotomy for the treatment of B lymphocyte diseases" Leukemia and Lymphoma, 43:1367-1373. (2002).	
	J46	VON BULOW and BRAM, "NF-AT activation induced by a CAML-interacting member of the tumor necrosis factor receptor superfamily" Science, 278: 138-141. (1997).	
	J47	LAABI ET AL., "A new gene, BCM, on chromosome 16 is fused to the interleukin 2 gene by a t(4;16)(q26;p13) translocation in a malignant T cell lymphoma" <i>The EMBO Journal</i> , 11:3897-3904. (1992).	
	J48	LAABI ET AL., "The BCMA gene, preferentially expressed during B lymphoid maturation, is bidirectionally transcribed" Nucleic Acids Research, 22:1147-1154. (1994).	
	J49	MADRY ET AL., "The characterization of murine BCMA gene defines it as a new member of the tumor necrosis factor receptor superfamily" International Immunology, 10:1693-1702. (1998).	
	J50	GRAS ET AL., "BCMAp: an integral membrane protein in the Golgi apparatus of human mature B lymphocytes" International Immunology, 7:1093-1106. (1995).	
	J51	Table setting out SEQ ID Nos (provided by Opponent I).	
	J52	PATEL ET AL., "Engineering an APRIL-specific B cell maturation antigen" The Journal of Biological Chemistry, 279:16727-16735. (2004).	
	J53	MUKHOPADHYAY ET AL., "Identification and characterization of a novel cytokine, THANK, a TNF Homologue that activates Apoptosis, Nuclear factor-kappaB, and c-Jun NH2-terminal Kinase" The Journal of Biological Chemistry, 274:15978-15981. (1999).	
	J54	Clustal V Alignment of human and mouse TACI (provided by Opponent I).	
BEB	J55	BODMER ET Al, "The molecular architecture of the TNF superfamily" Trends in Biochemical Sciences, 27:19-26. (2002).	

Examiner		i Date i	
[CYGIIIIIIIII		h =	
I Cianatura I	/Bridget E. Bunner/	Considered	07/19/2006
Signature	,	Considered	01/25/2000

PTC/S8/08a/b (07-05)
Approved for use through 07/31/2006. OMB 0851-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Sub	stitute for form 1449A/B/	PTO			Complete if Known
300				Application Number	09/589,288
II.	IFORMATIO	N DIS	CLOSURE	Filing Date	June 8, 2000
	STATEMENT BY APPLICANT			First Named Inventor	Guo-Liang Yu
				Art Unit	1647
	(Use as many	sheets as ne	ecessary)	Examiner Name	B.E. Bunner
Sheet	3	of	5	Attorney Docket Number	PF343P3C7

		NON PATENT LITERATURE DOCUMENTS							
xaminer nitials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T						
	J56	HYMOWITZ, ET AL., "Structures of APRIL-receptor complexes: like BCMA, TACI employs							
BEB		only a single cysteine-rich domain for high affinity ligand binding" The Journal of Biological							
			emistry, 280:7218-7227, (2005), with Tables S1-S4 and Fig. S1 as published in the online						
version of this article available at http://www.jbc.org. BEB J57 Sequence alignment of "Prosite" sequence (D1) and SEQ ID NO: 10 of EP 1 141 274 B1. J58 Further experimental evidence concerning anti-TACI antibodies of [EP 1 141 274 B1] Patent									
BEB	J57	Sequence alignment of "Prosite" sequence (D1) and SEQ ID NO: 10 of EP 1 141 274 B1.	_						
- 1	J58	Further experimental evidence concerning anti-TACI antibodies of [EP 1 141 274 B1] Patent	l						
BEB	Example 18 (Zymogenetics' unpublished data).								
	J59	GROSS ET AL., "TACI-Ig neutralizes molecules critical for B cell development and							
	•	autoimmune disease: Impaired B cell maturation in mice lacking BLyS" Immunity, 15:289-302.	l						
BEB		2001).							
	J60	Human Genome Science Inc.'s Reply filed in the European Patent Office on September 19,	Π						
BEB		2005 in conjunction with its Opposition of EP Patent No 1 146 892.	<u> </u>						
1	J61	DELVES AND ROITT, Encyclopedia of Immunology. 2 nd ed. Academic Press Inc. pp 1554-							
		1559. (1998).	1						
1	J62	JANEWAY AND TRAVERS, Immunobiology: The Immune System in Health and Disease.	Γ						
1		Current Biology Ltd./Garland Publishing, London. pp 5:28. (1994).	1						
-	J63	REED ET AL., "Modulating Apoptosis Pathways in Low Grade B-Cell Malignancies Using	 						
	505	Biological Response Modifiers" Seminars in Oncology, 29:10-24. (2002).	l						
+	J64	HUARD ET AL, "BAFF production by antigen-presenting cells provides T cell co-stimulation"	┢						
	J04	International Immunology, 16:467-475. (2004).	ı						
	J65	NG ET AL., "B Cell-Activating Factor Belonging to the TNF Family (BAFF)-R Is the Principal	╁╴						
	Jos	BAFF Receptor Facilitating BAFF Costimulation of Circulating T and B Cells" Journal of	l						
		Immunology, 173:807-817. (2004).	1						
+	ICC	BATTEN ET AL., "The role of BAFF in Autoimmunity: Is it just a B cell story?" The Midwinter	┝						
1 1	J66	BATTEN ET AL., The role of BAFF in Autoimmus; is in Just a Delit story? The influence	1						
	100	Conference of Immunologists at Asilomar, Pacific Grove, CA (January 22-25, 2005).	╀						
	J67	DAVIDSON and DIAMOND, "Autoimmune Diseases" New England Journal of Medicine,	1						
_		345:340-350. (2001).	├-						
Li	J68	JANEWAY AND TRAVERS, Immunobiology: The Immune System in Health and Disease.	1						
_		Current Biology Ltd./Garland Publishing, London. pp. 12:1-12:19. (1997).	╀						
	J69	TSOKOS, G.C. "Lymphocytes, cytokines, inflammation, and immune trafficking" Current							
		Opinion in Rheumatology, 7:376-383. (1995).	↓-						
1 1	J70	PANAYI, G.S. "The Pathogenesis of Rheumatoid Arthritis: From Molecules to the Whole	ł						
		Patient* British Journal of Rheumatology, 32:533-536. (1993).	┖						
	J71	SMITH ET AL., Principals of Biochemistry: General Aspects. McGraw Hill Book Company,	l						
		New York. pp. 194-197. (1983).	L						
	J72	HARLOW AND LANE, "Antibody Capture Assays-Comparing Antibody Binding Sites Using an	l						
1		Antibody Competition Assay", Antibodies: A Laboratory Manual. Cold Spring Harbor	١						
		Laboratory. pp. 567-569. (1988).	<u> </u>						
	J73	WELLS, J.A., "Additivity of Mutational Effects in Proteins", Biochemistry, 29(37):8509-8517.	1						
		(1990).	L						
	J74	NGO ET AL., Computational Complexity, Protein Structure Prediction and the Levinthal	1						
		Paradox. The Protein Folding Problem and Tertiary Structure Prediction, pp. 492-495. (1994).	L						
	J75	ELGERT, K., (1996) Immunology: Understanding the Immune System. Wiley-Liss: New York.	Γ						
		p. 24							
-	J76	BORK ET AL "Go hunting in sequence databases but watch out for the traps", Trends in	Т						
BEB	2.0	Genetics, 12:425-7. (1996).	1						
		Date	_						
xaminer									

PTO/SB/08a/b (07-05)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Sut	ostitute for form 1449A/B/F	OTO.			Complete If Known
300	331111C 101 101111 144374 C87			Application Number	09/589,288
IN	FORMATION DISCLOSUR		SCLOSURE	Filing Date	June 8, 2000
S	STATEMENT BY APPLICANT			First Named Inventor	Guo-Liang Yu
				Art Unit	1647
	(Use as many sheets as necessary)		necessary)	Examiner Name	B.E. Bunner
Sheet	4	of	5	Attorney Docket Number	PF343P3C7

		NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book,				
Examiner Cite Initials No.		magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publishe and/or country where published.				
BRB	J77	SMITH ET AL., "The challenges of genome sequence annotation or 'The devil is in the details", Nature Biotechology, 15:1222-3. (1997).				
	J78	DOERKS ET AL., "Protein Annotation: Detective Work for Function Prediction", Trends in Genetics, 14:248-250. (1998).				
	J78	BRENNER, S.E., "Errors in Genome Annotation" Trends in Genetics, 15:132-3. (1999).				
	J79	SKOLNICK ET AL., "From genes to protein structure and function: novel applications of computational approaches in the genome era" <i>Trends in Biotechnology</i> , 18: 34-9. (2000).				
	J80	BORK ET AL., "Powers and pitfalls in sequence analysis: the 70% hurdle" Genome Research, 10:398-400. (2000).				
	J81	TRIBOULEY ET AL., "Characterization of a New Member of the TNF Family Expressed on Antigen Presenting Cells" <i>Biological Chemistry</i> , 380: 1443-7. (1999).				
	J82	ASHKENAZI ET AL., "Response to 'Secreted IgM versus BLyS in germinal center formation" Nature Immunology, 1:179. (2000).				
	J83	BATTEN ET AL., "BAFF Mediates Survival of Peripheral Immature B Lymphocytes" The Journal of Experimental Medicine. 192:1453-65. (2000).				
	J84	WARE, "APRIL and BAFF Connect Autoimmunity and Cancer" The Journal of Experimental Medicine. 192:F35-F38. (2000).				
	J85	DORNER and PUTTERMAN, "B Cells, BAFF/zTNF4, TACI and Systemic Lupus Erythematosus" Arthritis Research 3:197-9. (2001).				
	J86	SIEGEL and LENARDO, "To B or not to B: TNF family signaling in lymphocytes" Nature				
	J87	LIU ET AL., "Crystal structure of sTALL-1 reveals a virus-like assembly of TNF family ligands" Cell, 108:383-394. (2002).				
	J88	KARPUSAS ET AL., "Crystal structure of extracellular human BAFF, a TNF family member that stimulates B lymphocytes" Journal of Molecular Biology, 315:1145-1154. (2002).				
	J89	OREN ET AL., "Structural basis of BLyS receptor recognition" Nature Structural Biology, 9:288-292. (2002).				
	J90	LIU ET AL., "Ligand receptor binding revealed by the TNF family member Tall-1" Nature, 423:49-56. (2003).				
	J91	HEPPELER ET AL., "Receptor Targeting for Tumor Localisation and Therapy with Radiopeptides" Current Medicinal Chemistry, 7:971-994. (2000).				
	J92	Genbank Accession No. Q9Y275. (1999). Shu et al., 16 October 2001.				
	J93	DENARDO ET AL., "Comparison of 1, 4, 7, 10-Tetraazacyclododecane-N, N', N"-tetraacetic acid (DOTA)-Peptide-ChL6, a Novel Immunoconjugate with Catabolizable Linker, to 2 iminothiolane-2-'p-(Bromoacetamido)benzyl]-DOTA-ChL6 in Breast Cancer Xenographs Clinical Cancer Research, 4:2483-2490. (1998).				
	J94	STOHL ,WILLIAM, "Blysfulness does not equal blissfulness in systemic tupus erythematosus: a therapeutic role for BLyS antagonists" <i>Current Directions in Autoimmun</i> ity, 8:289-304. (2005).				
	J95	BAKER, KEVIN P., "Blys-an essential survival factor for B cells: basic biology, links to pathology and therapeutic target" Autoimmunity Reviews, 3:368-375. (2004).				
	J96	KEHRL ET AL., "Effect of tumor necrosis factor alpha on mitogen-activated human B cells" Journal of Experimental Medicine, 166:786-791. (1987).				
BEB	J97	LOTZ ET AL., "The nerve growth factor/tumor necrosis factor receptor family" Journal of Leukocyte Biology, 60:1-7. (1996).				

Examiner		Date	
Signature	/Bridget E. Bunner/	Considered	07/19/2006

PTO/SB/08a/b (07-05)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Subst	titute for form 1449A/E	VPTO		Complete if Known		
Subst	uide for form 1440742	#1 1 0		Application Number	09/589,288	
IN	FORMATIC	ON DISC	LOSURE	Filing Date	June 8, 2000	
STATEMENT BY APPLICANT		First Named Inventor	Guo-Liang Yu			
•		• • • • •		Art Unit	1647	
(Use as many sheets as necessary)		Examiner Name	B.E. Bunner			
Sheet	5	of	5	Attorney Docket Number	PF343P3C7	

		NON PATENT LITERATURE DOCUMENTS
BEB		Molecular Biology of the Cell, Second Edition, edited by Alberts et al., Garland Publishing, Inc., New York, pp. 117-118. (1989).
BEB	199	MARIETTE ET AL., "The Level of BLyS (BAFF) Correlates With the Titre of Autoantibodies in Human Sjogren's Syndrome" Annual Rheumatology Discussion, 62:168-171. (2003).

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Examiner /Bridget B. Bunner/ Date Considered 07/19/2006				
15000000 /Deldact D Dunnow/	Evernines		IDate I	
Considered V//17/2000	CXAIIIIII	/Dwident W Dunner/		07/10/2006
	61	/bridget b. bunner/	Concidered	0//13/2000
[Signature]	Signature		Toolisideled	

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Sheet

Substitute for form 1449A/B/PTO

PTO/SB/08a/b (06-03)
Approved for use through 07/31/2003. OMB 0851-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
the Paperwork Reduction Act of 1985, no persons are required to respond to a collection of information unless it contains a valid CMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

of

(Dee as many sheets as necessary)

	Complete if Known					
Application Number 09/589,288-Conf. #1519						
Filing Date	June 8, 2000					
First Named Inventor	Guo-Liang Yu					
Art Unit	1647					
Examiner Name	B. Bunner					
Attorney Docket Number	PF343P3C5					

			U.S. PA	TENT DOCUMENTS		
Examiner Initials*	Cite No.1	 Code ² (If known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	$\overline{/}$	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		 -t				

	,	FOF	EIGN PATENT	DOCUMENTS /	
Examiner Initials*	Cite No.	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (if kno	Publication Date Wn) MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

*EXAMINER: Initial if reference considered, whether or not chetion is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication applicant. Applicant's prique citation designation number (optional). *See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). *For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. *Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. *Applicant is to place a check mark here if English language Translation is attached.

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No.1	magazine, journal, senal, symposium, catalog, etc), date, page(s), volunte-issue hamber(s), page(s),	T²
	C1	Waldmann, TA, "Immunotherapy: Past, Present and Future," Nature Medicine 9:269-277, (2003).	
	C2	Janeway, C. & P. Travers. (1994) Immunobiology: The Immune System in Health and Disease, (Current Biology Ltd./Garland Publishing, Landon), pp 1:15, 1:16 and 11:19.	
	СЗ	Weinblatt, ME et al., Mechotrexate in rheumatoid arthritis. A five-year prospective multicenter	
	C4	Wise, CM et al., Methotrexate in nonrenal lupus and undifferentiated connective tissue disease - a review of 36 patients. The Journal of Rheumatology. (1996) 23:1005-1010.	
	C5	Brazelton, TR and RE Morris. Molecular mechanism of action of new xenobiotic immunosuppressive drugs: tacrolimus (FK506), sirolimus (rapartycin), mycophenolate mofetil and leftunorade. Current Opinion in Immunology. (1996) 8:710-720.	
	C6	Goldblum R, Therapy of rheumatold arthritis with mycophenolate mofetil. Clinical and Experimental Rheumatology. (1993) 11 suppl 8:S117-119.	
	C7	Circle Circle Community Community Circle Community Community Circle Commun	
<u> </u>	C8	Huerd, et al., T cell costimulation by the TNF ligand BAFF. The Journal of Immunology. (2001) 167(11):6225-31.	
	C9	Kayagaki, N et al., BAFF/BLyS receptor 3 binds the B cell survival factor BAFP ligand through a discrete surface loop and promotes processing of NF-kappaB2. Immunity (2008) 10:515-24.	
	C16	Abbas et al., Cellular and Molecular Immunology (W.B. Saunders Company: Philatelphia) 1991, pp. 362 and 365.	

*EXAMPNER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

pplicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.

Examiner		Date	
Signature	/Bridget E. Bunner/	Considered	07/19/2006

MAR 1 7 2006

PTO/SB/08a/b (#8-03)

Approved for use through 07/31/2006. OMB 08/1-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB copied number.

Substitute for form 1449A/B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Use as many sheets as necessary)

of Sheet

	Complete if Known
Application Number	09/589,288-Conf. #15/9
Filing Date	June 8, 2000
First Named Inventor	Guo-Liang Yu
Art Unit	1647
Examiner Name	B. E. Bunne
Attorney Docket Number	PF343P325

		_		U.S. PA	TENT DOCUMENTS	
Examiner Initials*	Cite No.1		iment Number Ind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		· · · · · · · · · · · · · · · · · · ·				

1

	FOREIGN PATENT DOCUMENTS								
_	-	Foreign Patent Dokum	ent	Publication	Name of Patentee or	Pages, Columns, Lines, Where Relevant Passages			
Examiner Initials*	Cite No.1	Country Code ³ -Number ⁴ -Kind Co	de" (if known)	Date MM-DD-YYYY	Applicant of Cited Document	or Relevant Figures Appear			
			1		7				

*EXAMINER: Initial if reference considered, whether or not dilation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emparor must precade the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WinO Standard ST.16 if possible. Applicant is to place a check mark here if English language Translation is attached.

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No.1	Include name of the author (in CAP/TAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or county where published.	T².
	D1	Baker et al., "Generation and Characterization of LymphoStat-B, a Human Monoclonal Antibody That Antagonizes the Bioactivities of Bl. ymphocyte Stimulator," Arthritis & Rheumatism, 48(11):3253-3265 (Nov. 2003).	
	D2	Furle, R. et al., "Salety, Pharmacokinetic and Pharmacodynamic Results of a Phase 1 Single and Double Dose, Escalation Study of LymphoStat-B (Human Monoclonal Antibody to BLyS) in SLE Patients." 67th Annual American College of Rheumatology Scientific Meeting, October 23-28, 2003, Orlando, Florida.	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw this through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

signation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner		Date	
Signature	/Bridget E. Bunner/	Considered	07/19/2006

PRIDEMARK

PTO/SB/08a/b (08-03)

Approved for use through 07/31/2008. OMB 0651-003:
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCI
spond to a collection of information unless it contains a valid OMB control number.

7		14400/07	DTO.			Complete if Known
Sepsuit	Shostitute for form 1449A/B/PTO INPORMATION DISCLOSURE				Application Number	09/589,288-Conf. #1519
INP					Filing Date	June 8, 2000
• •	STATEMENT BY APPLICANT				First Named Inventor	Guo-Liang Yu
017	7.7				Art Unit	1647
(Use as many sheets as necessary)			necessary)	Examiner Name	B. E. Bunner	
Sheet .	1	$\overline{}$	of	1	Attorney Docket Number	PF343P3C5

			U.S. PA	TENT DOCUMENTS	
Examiner Initials*	Cite No.1	Document Number Number-Kind Code ² (Kinown)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	E1	6.869,605	03-22-2005	Browning et al.	
	E2	6,875,846	04-05-2005	Rennert et al.	
			1		

		FOREIGN	PATENT I	DOCUMENTS		
Examiner Initials*	Cite No.1	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (Il known) MM	Publication Date N-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	7°
					<u> </u>	
					<u> </u>	L_
						<u> </u>
						<u> </u>

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicage. *Applicant's unique citation designation number (optional). *See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. *Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). *For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. *Skind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. *Applicant is to place a check mark here if English language Translation is attached.

	-	NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No. Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (be magazine, journal, serial symposium, catalog, etc.), date, page(s), jolume-issue number(s), publisher, citangler and/or country where published.					
	E3	Biogen Inc. and Apoxis SA's Response (including Annexes A and B and the Main Request containing a substitute set of claims) to Human Genome Sciences and Serono's Oppositions of EP Patent No. 1146892. The Response was filed in the European Patent Office on March 14, 2005.				

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation considered. Include copy of this form with next communication to applicant. Knot in conformance and not

on designation number (optional). ²Applicant is to place a check mark here if English language Translation is 'Applicant's unique cit

		Date	9
Examiner			07/10/2006
	/Bridget B. Bunner/	Considered	07/19/2006
Signature	/2110get 2. Damiel/	100.00.00	

MAR 1 7 2006

PTO/SB/08a/b (09/03)
Approved for use through 07/31/2008. OMB 0653/0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

1 of Sheet

(Complete if Known
Application Number	09/589,288-Conf. #151/9
Filing Date	June 8, 2000
First Named Inventor	Guo-Liang Yu
Art Unit	1647
Examiner Name	B. E. Bunner
Attorney Docket Number	PF343P305

		-		U.S. PA	TENT DOCUMENTS	
Examiner Initials*	Cite No.1		ent Number Cde ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
			$\overline{}$			

		FOREI	GN PATENT	DOCUMENTS	
Examiner Initials*	Cite No.1	Foreign Patent Document Country Codes - Number - Kind Codes (# known)	Publication Date MM-DD-YYYY	pame of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	F1	WO-00/58362		HUMAN GENOME SCIENCES, INC.	

*EXAMINER: Initial if reference considered, whether or not clintion is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. "Aprilicant's unique citation designation number (optional). 3 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Enter Officert's unique citation designation number (optional). 3 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. See Kinds Codes of USPTO Patent Documents, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Skind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English language Translation is attached.

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
	F2	WPI/DERWENT Accession No. 2000-572093.	<u> </u>
		Supplementary Partial European Search Report, European Application No. EP 00 90 8739, mailed June 30, 2005.	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 619. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Date Examiner 07/19/2006 /Bridget B. Bunner/ Considered Signature

number (optional). ²Applicant is to place a check mark here if English language Translation is attached. ¹Applicant's unique citation designation

MAR 1 7 2006

PTO/SB/08a/b (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

_	substitute for form 1449A/B/PTQ			equired to respond to a collection of information unless it contains a valid Civils control Complete if Known		
Speniar	6 101 101111 144 <i>8/401</i>			Application Number	09/589,288-Conf. #1519	
INFORMATION DISCLOSURE				Filing Date	June 8, 2000	
	STATEMENT BY APPLICANT			First Named Inventor	Guo-Liang Yu	
317	7			Art Unit	1647	
(Usi as many sheets as necessary)			necessary)	Examiner Name	B. E. Bunner	
Sheet	1	of	1	Attorney Docket Number	PF343P3C5	

			U.S. PATE	NT DOCUMENTS	
Examiner Initials*	Cite No.1	Document Number Number-Kind Code (Innown)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Unes, Where Relevant Passages or Relevant Figures Appear
ļ					

		POREIG	IN PATENT	DOCUMENTS		
Examiner Initials*	Cite No.¹	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Unes, Where Relevant Passages or Relevant Figures Appear	Τ ⁶
<u> </u>	 		<u> </u>			
 	l		$\overline{}$			
						

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant's unique citation designation number (optional). ³ See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 801.04. ³ Enter Office that assed the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.18 it possible. ⁸ Applicant is to place a check mark here if English language Translation is attached.

	NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No.1	Include name of the author (ir CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T²		
	G1	ZymoGenetics' Observations in Reply (158 pages) to Oppositions of EP Patent No. 1141274 lodged by Corixa Corporation, Human Genome Sciences, inc., Genentech, Inc., and Biogen Idec, Inc. The Observations in Reply was filed in the European Patent Office on June 7, 2005.			
	G2	STOHL, W., "A therapeutic role for BLyS antagonists," Lupus, 13:3 7-322 (2004).			
	G3	NOVAK et al., "Expression of BLyS and its receptors in B-cell non-Hodgkin lymphoma: correlation with disease activity and patient outcome," Blood, 104(8):2247-2253 (2004).			
	G4	European Search Report, European Application No. EP 05 01 2261, mailed August 8, 2005.			

*EXAMINER: initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if considered. Include copy of this form with next communication to applicant. ton bne sonsmortnos ni tog

Applicant's unique coation designation number (optional). Applicant is to place a check mark here if English language Translation is a

			·
Eversions		Date	
Examiner	/Bridget E. Bunner/	Considered	07/19/2006
Signature	/Bridget B. Buimer/	Considered	0,725,2000

MAR 1 7 2006 A TANDENT

Sheet

of

1

PTO/SB/08a/b (07-95) Approved for use through 07/31/2006. OMB 0651-9031

B. E. Bunner

PF343P3C5

Under the Paperwork Reduction Act of 1995, no persons are require	U.S. Patent and Trad ed to respond to a collection of	lemark Office; U.S. DEPARTMENT OF COMMI Information unless it contains a valid OMB control nu	
Substitute for form 1449A/B/PTO	Complete If Known		
\	Application Number	09/589,288-Conf. #1519	
INFORMATION DISCLOSURE	Filing Date	June 8, 2000	
STATEMENT BY APPLICANT	First Named Inventor	Guo-Liang Yu	
\	Art Unit	1647	
Vilse as many sheets as no cessary)			

Examiner Name

Attorney Docket Number

U.S. PATENT DOCUMENTS Docu ent <u>Number</u> Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear **Publication Date** Examiner Cite Name of Patentee or MM-DD-YYYY initiais* de[®] (#known) No.1 Number-Kind a Applicant of Cited Documer

			FOREI	GN PATENT	DOCUMENTS/		
	Cite	Foreign Patent Dour	ment	Publication	Name of Patentee or	Pages, Columns, Lines,	Π
	No.	Country Code ¹ -Number ¹ -Kind Code ¹ (if known)	Date MM-DD-YYYY	Applicant of Cited Document	Where Relevant Passages or Relevant Figures Appear	7*	
	l1	WQ-02/18620		03-07-2002	Human Genome Sciences, Inc.		┌

*EXAMINER: Initial if reference considered, whether or not cliation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication in applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.usoto.gov or MPEP 901.04. There Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the Indication of the year of the reign of the Empery must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English tanguage Translation is attached.

	NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No.1 Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (bot magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, cit and/or country where published.					
	12	SCHALLER et al., "Characterization of apxIVA, a new RTX determinant of Actinobacillus pleuropneumoniae," Microbiology, 145:2105-2116 (1999).				
	13	CHEN et al., "Expression vectors for affinity purification and radiolabeling of proteins using Escherichia coli as host," Gene, 139:73-75 (1994).				
	14	Supplementary European Search Report, European Application No. 02 78 6413, mailed December 20, 2006.				
	15	Human Genome Sciences, Inc.'s Reply filed in the European Patent Office on November 4, 2005 in conjunction with its Opposition of EP Patent No. 1141274 and copies of supporting documents D41-D43.				

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conficensidered. Include copy of this form with next communication to applicant. ed, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

F				
Examiner	/Deidest B Burnsy/	Date		
Signature	/Bridget B. Bunner/	Considered	07/19/2006	
		[0013306180]	0.757,500	

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Tra nstation is attached.

PTO/SB/08a/b (06-03)

Approved for use through 07/31/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE spond to a collection of information unless it contains a valid OMB control number.

Sut	stitute for form 1449A/B/PT	0			Complete If Known
	Substitute to form 1440/45/110		Application Number	09/589,288-Conf. #1519	
11	IFORMATION	l DI	SCLOSURE	Filing Date	June 8, 2000
S	INFORMATION DISCLOSURE STATEMENT BY APPLICANT		TEMENT BY APPLICANT Fire		Guo-Liang Yu RECEIVE
				Art Unit ·	1647 RECLIVE
	(Use as many sh	eets as	s necessary)	Examiner Name	B. Bunner DEC 0 8 2003
Sheet	1	of	1	Attorney Docket Number	PF343P3C5

Examiner Cite Document Number Publication Date Name of Patentee or Relevant Passages or Relev				U.S. PAT	TENT DOCUMENTS	TECH CENTER 1600/2
riguies Appear	Examiner Initials*	Cite No.1	Document Number Number-Kind Code ² (# known)			

		FOREI	GN PATENT	DOCUMENTS		
Examiner Initials*	Cite No.1	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	7
					1	ı

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the Indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language Translation is attached.

		NON PATENT LITERATURE DOCUMENTS	
Examiner Cite Initials No. C1		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
		Waldmann, TA, "Immunotherapy: Past, Present and Future," Nature Medicine 9:269-277, (2003).	
	C2	Janeway, C. & P. Travers. (1994) Immunobiology: The Immune System in Health and Disease, (Current Biology Ltd./Garland Publishing, London), pp 1:15, 1:16 and 11:19.	
	СЗ	Weinblatt, ME et al., Methotrexate in rheumatoid arthritis. A five-year prospective multicenter study. Arthritis and Rheumatism. (1994) 37:1492-1498.	
	ð.	Wise, CM et al., Methotrexate in nonrenal lupus and undifferentiated connective tissue disease - a review of 36 patients. The Journal of Rheumatology. (1996) 23:1005-1010.	
	C5	Brazelton, TR and RE Morris. Molecular mechanism of action of new xenobiotic immunosuppressive drugs: tacrolimus (FK506), sirolimus (rapamycin), mycophenolate mofetil and leflunomide. Current Opinion in Immunology. (1996) 8:710-720.	
	C6	Goldblum, R, Therapy of rheumatoid arthritis with mycophenolate mofetil. Clinical and Experimental Rheumatology. (1993) 11 suppl 8:S117-119.	
	C7	Ciruelo, E et al., Cumulative rate of relapse of lupus nephritis after successful treatment with cyclophosphamide. Arthritis and Rheumatism. (1996) 39:2028-2034.	
	C8	Huard, et al., T cell costimulation by the TNF ligand BAFF. The Journal of Immunology. (2001) 167(11):6225-31.	
	C9	Kayagaki, N et al., BAFF/BLyS receptor 3 binds the B cell survival factor BAFF ligand through a discrete surface loop and promotes processing of NF-kappaB2. Immunity (2002) 10:515-24.	
BEB	C10	Abbas et al., Cellular and Molecular Immunology (W.B. Saunders Company: Philadelphia) 1991, pp. 362 and 365.	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner		Date	
	/Bridget E. Bunner/	1 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2	ı
Signature	/DIIdget Bi Damel/	Considered 07/13/2006	

PTO/SB/08a/b (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE to Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

1647

Usafe the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Complete if Known

Application Number 09/589,288-Conf. #1519

INFORMATION DISCLOSURE

Filing Date June 8, 2000

First Named Inventor Guo-Liang Yu

Art Unit

(Use as many sheets as necessary)

Sheet 1 of 1 Attorney Docket Number PF343P3C5

	U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No.1	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear		
					•		

	FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No.1	Foreign Patent Document Country Code*-Number*-Hind Code* (# known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. *Applicant's unique citation designation number (optional). *See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. *Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). *For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. *Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. *Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS						
Examiner Initials	Cite No.1	include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T			
BEB	D1	Baker et al., "Generation and Characterization of LymphoStat-B, a Human Monoclonal Antibody That Antagonizes the Bioactivities of B Lymphocyte Stimulator," <i>Arthritis</i> & Rheumatism, 48(11):3253-3265 (Nov. 2003).				
BEB	D2	Furie, R. et al., "Safety, Pharmacokinetic and Pharmacodynamic Results of a Phase 1 Single and Double Dose-Escalation Study of LymphoStat-B (Human Monoclonal Antibody to BLyS) in SLE Patients." 67th Annual American College of Rheumatology Scientific Meeting, October 23-28, 2003, Orlando, Florida.				

^{*}EXAMINER: initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Examiner Signature	/Bridget E. Bunner/	Date Considered	07/13/2006
Signature		[Considered]	

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

DIP E COR

PTO/SB/08a/b (08-03)
Approved for use through 07/31/2008. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 1

Complete if Known						
Application Number	09/589,288-Conf. #1519					
Filing Date	June 8, 2000					
First Named Inventor	Guo-Liang Yu					
Art Unit	1647					
Examiner Name	B. E. Bunner					
Attorney Docket Number	PF343P3C5					

	U.S. PATENT DOCUMENTS							
Examiner Cite Document Number Publication Date Name of Patentee or Relevant Passages or R								
Initials*	No.	Number-Kind Code ² (if known)	MM-DD-YYYY	Applicant of Cited Document	Relevant Passages or Relevant Figures Appear			
BEB	E1	6,869,605	03-22-2005	Browning et al.				
BEB	E2	6,875,846	04-05-2005	Rennert et al.				

	FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No.	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁶ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T°		
						H		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS						
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²			
BEB	E3	Biogen Inc. and Apoxis SA's Response (including Annexes A and B and the Main Request containing a substitute set of claims) to Human Genome Sciences and Serono's Oppositions of EP Patent No. 1146892. The Response was filed in the European Patent Office on March 14, 2005.				

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Examiner Signature	/Bridget B. Bunner/	Date Considered	07/13/2006

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.



PTO/SB/08e/b (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Sut	stitute for form 1449A/B/P	TO		Complete if Known		
				Application Number	09/589,288-Conf. #1519	
11	NFORMATIO	N DI	SCLOSURE	Filing Date	June 8, 2000	
S	TATEMENT	BY /	APPLICANT	First Named Inventor	Guo-Liang Yu	
				Art Unit	1647	
	(Use as many si	heets as	s necessary)	Examiner Name	B. E. Bunner	
Sheet	1	of	1	Attorney Docket Number	PF343P3C5	

	U.S. PATENT DOCUMENTS					
Cuaminar	24-	Document Number	Publication Date	Name of Patentee or	Pages, Columns, Lines, Where	
Examiner Cite Initials* No.	No.	Number-Kind Code ² (if known)	MM-DD-YYYY	Applicant of Cited Document	Relevant Passages or Relevant Figures Appear	

		FOREI	GN PATENT	DOCUMENTS		
Examiner Initials*	Cite No.1	Foreign Patent Document Country Code ³ -Number ⁴ +Vind Code ⁵ (II known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Τ°
BEB	F1	WO-00/58362		HUMAN GENOME SCIENCES, INC.		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language Translation is attached.

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No.¹	Include name of the author (in CAPITAL LETTERS), little of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
BEB	F2	WPI/DERWENT Accession No. 2000-572093.	
BEB	F3	Supplementary Partial European Search Report, European Application No. EP 00 90 8739, mailed June 30, 2005.	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

	=		
Examiner		Date	
	/Bridget E. Bunner/	.	07/13/2006
Signature	/Biluget a. Bunner/	Considered	07/25/2000

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Alls , Mg Sid

PTO/SB/08a/b (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

The Bases work Report of Information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 1

	Complete if Known
Application Number	09/589,288-Conf. #1519
Filing Date	June 8, 2000
First Named Inventor	Guo-Liang Yu
Art Unit	1647
Examiner Name	B. E. Bunner
Attorney Docket Number	PF343P3C5

U.S. PATENT DOCUMENTS							
ite lo.'	Document Number Number-Kind Code ² (# known)	Publication Date MM-OD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear			
4							
	te o.'	te	te Publication Date	te Name of Patentee of			

		FOREIG	SN PATENT D	OCUMENTS		
Examiner Initials*	Cite No.1	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁶ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T°
						\vdash
					<u> </u>	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.18 if possible. Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS				
Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²		
G1	ZymoGenetics' Observations in Reply (158 pages) to Oppositions of EP Patent No. 1141274 lodged by Corixa Corporation, Human Genome Sciences, Inc., Genentech, Inc., and Biogen Idec, Inc. The Observations in Reply was filed in the European Patent Office on June 7, 2005.			
G2	STOHL, W., "A therapeutic role for BLyS antagonists," Lupus, 13:317-322 (2004).	\Box		
G3	NOVAK et al., "Expression of BLyS and its receptors in B-cell non-Hodgkin lymphoma: correlation with disease activity and patient outcome," <i>Blood</i> , 104(8):2247-2253 (2004).			
G4	European Search Report, European Application No. EP 05 01 2261, mailed August 8, 2005.			
	G1 G2 G3	Cite No.¹ Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. G1 ZymoGenetics' Observations in Reply (158 pages) to Oppositions of EP Patent No. 1141274 lodged by Corixa Corporation, Human Genome Sciences, Inc., Genentech, Inc., and Biogen Idec, Inc. The Observations in Reply was filed in the European Patent Office on June 7, 2005. G2 STOHL, W., "A therapeutic role for BLyS antagonists," Lupus, 13:317-322 (2004). G3 NOVAK et al., "Expression of BLyS and its receptors in B-cell non-Hodgkin lymphoma: correlation with disease activity and patient outcome," Blood, 104(8):2247-2253 (2004).		

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Examiner	/Bridget E. Bunner/	Date	an /a a /a a a
Signature	, 3 ,	Considered	07/19/2006

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.



PTO/SB/08a/b (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Sul	bstitute for form 1449A/B	/PTO			Complete if Known
"				Application Number	09/589,288-Conf. #1519
1 11	NFORMATIC	N DIS	CLOSURE	Filing Date	June 8, 2000
S	TATEMENT	BY A	PPLICANT	First Named Inventor	Guo-Liang Yu
				Art Unit	1647
1	(Use as many	sheets as	necessary)	Examiner Name	B. E. Bunner
Sheet	1	of	1	Attorney Docket Number	PF343P3C5

	U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No.1	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear		

	•	FOREIC	ON PATENT D	OCUMENTS		
Examiner	Cite	Foreign Patent Document	Publication Date	Name of Palentee or	Pages, Columns, Lines, Where Relevant Passages	
Initials*	No.	Country Code ³ -Number ⁴ -Kind Code ⁶ (if known)	MM-DD-YYYY	Applicant of Cited Document	or Relevant Figures Appear	T
						\vdash
				· · · · · · · · · · · · · · · · · · ·		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WiPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document, by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

	NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²			
BEB	H1	Serono International SA's Reply filed in the European Patent Office on August 24, 2005 in conjunction with its Opposition of EP Patent No. 1146892.				
			Щ			

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Examiner	/Bridget B. Bunner/	Date	07/13/2006
	/pridger p. pumer/		I 0//13/2000 I
Signature		Considered	, ,
o.a.iataro		Toonsidered	

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08a/b (07-05)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Serwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO				Complete if Known		
				Application Number	09/589,288-Conf. #1519	
IN	IFORMATIO	N DIS	SCLOSURE	Filing Date	June 8, 2000	
S.	STATEMENT BY APPLICANT			First Named Inventor	Guo-Liang Yu	
				Art Unit	1647	
	(Use as many sheets as necessary)			Examiner Name	B. E. Bunner	
Sheet	1	of	1	Attorney Docket Number	PF343P3C5	

U.S. PATENT DOCUMENTS							
Examiner Initials*	Cite No.	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear		

	FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No.1	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (# known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear				
BEB	l1	WO-02/18620	03-07-2002	Human Genome Sciences, Inc.					

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

	NON PATENT LITERATURE DOCUMENTS						
Examiner Initials	Cite No.1	include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T2				
BEB	12	SCHALLER et al., *Characterization of apxIVA, a new RTX determinant of Actinobacillus pleuropneumoniae,* Microbiology, 145:2105-2116 (1999).					
	13	CHEN et al., "Expression vectors for affinity purification and radiolabeling of proteins using Escherichia coli as host," Gene, 139:73-75 (1994).					
	14	Supplementary European Search Report, European Application No. 02 78 6413, mailed December 20, 2005.					
BEB	15	Human Genome Sciences, Inc.'s Reply filed in the European Patent Office on November 4, 2005 in conjunction with its Opposition of EP Patent No. 1141274 and copies of supporting documents D41-D43.					

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

^{&#}x27;Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08a/b (08-03)
Approved for use through 07/31/2008. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Suit	estitute for form 1449A/B/	PTO		Complete if Known		
50.	SELECTOR COLLIN 1779/20/			Application Number	09/589,288	
l in	NFORMATIC	N DI	SCLOSURE	Filing Date	June 8, 2000	
S	TATEMENT	BY A	APPLICANT	First Named Inventor	Guo-Liang Yu	
				Art Unit	1647	
	(Use as many	sheets as	necessary)	Examiner Name	B.E. Bunner	
Sheet	1	of	1	Attorney Docket Number	PF343P3C5	

U.S. PATENT DOCUMENTS							
Examiner Initials*	Cite No.1	Document Number Number-Kind Code ² (# known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear		

	FOREIGN PATENT DOCUMENTS								
Sæminer initials*	Cite No.1	Foreign Patent Document Country Code*-Number*-Kind Code* (If known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T [®]			
				www		-			

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.usubo.gov or MPEP 901.04. ² Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ¹ For Japanese patent documents, the Indication of the year of the reign of the Emperor must precede the sextal number of the patent document. ⁵ Kind of document by the appropriate symbols as Indicated on the document under WIPO Standard ST.18 if possible. ⁵ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS						
Examiner Initials	Cite No.1	include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-Issue number(s), publisher, city and/or country where published.	T²			
BEB	L1	ZymoGenetics' opposition of EP Patent No 0 939 804 including copies of supporting documents D1-D27. Filed in the European Patent Office on May 17, 2006.				
BEB	L2	Serono International SA's opposition of EP Patent No 0 939 804 including copies of supporting documents D1-D17. Filed in the European Patent Office on May 17, 2006.				
BEB	L3	Eli Liliy and Company's opposition of EP Patent No 0 939 804 including copies of supporting documents D1-D16. Filed in the European Patent Office on May 17, 2006.				

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant.

Examiner	,	Date	07/13/2006
Signature	/Bridget B. Bunner/	Considered	' '

^{&#}x27;Applicant's unique citetion designation number (optional). 'Applicant is to place a check mark here if English tanguage Translation is attached.